The use of stromal vascular fraction (SVF), platelet-rich plasma (PRP) and stem cells in the treatment of osteoarthritis: an overview of clinical trials
Source abstract
Abstract
Osteoarthritis (OA) is a major cause of disability across the world, which its prevalence is relatively high in elder population. Current accepted therapies such as exercise, anti-inflammatory drugs and intra-articular inoculation of corticosteroids are aimed at controlling symptoms in the affected patients. Surgical options including arthroplasty, osteotomy and joint replacement are other choices of treatment, which are invasive and can be applied in case of failure of conventional therapies. In the last few decades, efforts to treat musculoskeletal diseases are being increasingly focused on regenerative cellular therapies. Stromal vascular fraction (SVF), which obtained from adipose tissue, contains a variety of cells include mesenchymal stem cells (MSCs) and has shown to be effective in cartilage repair. Autologous blood products such as platelet-rich plasma (PRP) act as an adjuvant of surgical treatment and its intra-articular delivery has shown beneficial effects for OA treatment. Given the efficacy of such treatment approaches in OA, this paper discusses both preclinical and clinical evidence with major focus on clinical trials.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Periodontal Regeneration and Treatments · Osteoarthritis Treatment and Mechanisms · Mesenchymal stem cell research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Genetics and Immunology, Faculty of Medicine, Urmia University of Medical Sciences
Cellular and Molecular Research Center, Urmia University of Medical Sciences
Department of Chemical Engineering, Northeastern University
Drug Applied Research Center, Tabriz University of Medical Sciences
Department of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences
References (80)
Show source-provided references
1. Man GS, Mologhianu G. Osteoarthritis pathogenesis – a complex process that involves the entire joint. J Med Life. 2014;7:37–41.
2. 10.1016/j.rehab.2016.01.00610.1016/j.rehab.2016.01.006 ↗
3. 10.1093/hmg/ddx30210.1093/hmg/ddx302 ↗
4. 10.1038/nrrheum.2016.6510.1038/nrrheum.2016.65 ↗
5. 10.1002/art.3927910.1002/art.39279 ↗
6. 10.1002/art.3918210.1002/art.39182 ↗
7. 10.1136/annrheumdis-2014-20629510.1136/annrheumdis-2014-206295 ↗
8. 10.1002/art.2730510.1002/art.27305 ↗
9. 10.1016/j.maturitas.2014.12.00310.1016/j.maturitas.2014.12.003 ↗
10. 10.1016/j.joca.2009.03.00210.1016/j.joca.2009.03.002 ↗
11. 10.1016/j.joca.2006.11.00910.1016/j.joca.2006.11.009 ↗
12. 10.1186/s13075-014-0466-410.1186/s13075-014-0466-4 ↗
13. 10.1016/j.rdc.2016.07.00410.1016/j.rdc.2016.07.004 ↗
14. 10.1155/2015/19241510.1155/2015/192415 ↗
15. 10.2147/JPR.S9209010.2147/JPR.S92090 ↗
16. 10.1056/NEJMcp05172610.1056/NEJMcp051726 ↗
17. 10.1001/jama.1997.0354025003302810.1001/jama.1997.03540250033028 ↗
18. 10.1002/art.2025610.1002/art.20256 ↗
19. 10.1016/j.carbpol.2014.03.03310.1016/j.carbpol.2014.03.033 ↗
20. 10.4081/or.2016.625610.4081/or.2016.6256 ↗
21. 10.1136/ard.54.5.37910.1136/ard.54.5.379 ↗
22. 10.1002/acr.2159610.1002/acr.21596 ↗
23. 10.1007/s00264-002-0330-z10.1007/s00264-002-0330-z ↗
24. El-Hakeim EH, Elawamy A, Kamel EZ, et al. Fluoroscopic guided radiofrequency of genicular nerves for pain alleviation in chronic knee osteoarthritis: a single-blind randomized controlled trial. Pain Phys. 2018;21:169–177.
25. Kim DH, Choi SS, Yoon SH, et al. Ultrasound-guided genicular nerve block for knee osteoarthritis: a double-blind, randomized controlled trial of local anesthetic alone or in combination with corticosteroid. Pain Phys. 2018;21:41–52.
26. 10.1016/j.rehab.2016.04.00310.1016/j.rehab.2016.04.003 ↗
27. Van Manen MD, Nace J, Mont MA. Management of primary knee osteoarthritis and indications for total knee arthroplasty for general practitioners. J Am Osteopath Assoc. 2012;112:709–715.
28. 10.1056/NEJMoa070833310.1056/NEJMoa0708333 ↗
29. 10.1038/boneres.2015.4010.1038/boneres.2015.40 ↗
30. 10.1053/joca.2002.080110.1053/joca.2002.0801 ↗
31. 10.3389/fimmu.2013.0020110.3389/fimmu.2013.00201 ↗
32. 10.1089/scd.2011.072210.1089/scd.2011.0722 ↗
33. 10.1002/jcp.2063610.1002/jcp.20636 ↗
34. 10.1016/j.knee.2012.04.00110.1016/j.knee.2012.04.001 ↗
35. 10.1186/s12967-017-1242-410.1186/s12967-017-1242-4 ↗
36. 10.1186/1752-1947-5-29610.1186/1752-1947-5-296 ↗
37. 10.1186/1471-2474-14-33710.1186/1471-2474-14-337 ↗
38. 10.7603/s40730-014-0002-910.7603/s40730-014-0002-9 ↗
39. 10.1016/j.arthro.2012.11.01710.1016/j.arthro.2012.11.017 ↗
40. 10.1007/s00167-013-2807-210.1007/s00167-013-2807-2 ↗
41. 10.1177/036354651452964110.1177/0363546514529641 ↗
42. Michalek J, Moster R, Lukac L, et al. WITHDRAWN: autologous adipose tissue-derived stromal vascular fraction cells application in patients with osteoarthritis. Cell Transpl. 2015;20:1–36.
43. 10.1089/biores.2016.002410.1089/biores.2016.0024 ↗
44. 10.1093/asj/sjv13510.1093/asj/sjv135 ↗
45. 10.1186/ar449310.1186/ar4493 ↗
46. 10.1007/s00264-009-0793-210.1007/s00264-009-0793-2 ↗
47. 10.1177/036354651141927810.1177/0363546511419278 ↗
48. 10.1016/j.biomaterials.2011.05.00210.1016/j.biomaterials.2011.05.002 ↗
49. 10.1002/jcp.2227410.1002/jcp.22274 ↗
50. 10.1002/jor.2200510.1002/jor.22005 ↗
51. 10.1177/194173811143180110.1177/1941738111431801 ↗
52. 10.1177/036354651247129910.1177/0363546512471299 ↗
53. 10.1016/j.apmr.2013.11.00610.1016/j.apmr.2013.11.006 ↗
54. 10.1016/j.arthro.2016.09.02410.1016/j.arthro.2016.09.024 ↗
55. 10.2147/DDDT.S15672410.2147/DDDT.S156724 ↗
56. 10.1111/1756-185X.1331510.1111/1756-185X.13315 ↗
57. 10.2147/CIA.S14775710.2147/CIA.S147757 ↗
58. 10.3233/BMR-17106610.3233/BMR-171066 ↗
59. 10.1016/j.ijsu.2018.03.07810.1016/j.ijsu.2018.03.078 ↗
60. 10.1177/107110071770037710.1177/1071100717700377 ↗
61. 10.1007/s00167-011-1837-x10.1007/s00167-011-1837-x ↗
62. 10.1038/nrrheum.2013.10910.1038/nrrheum.2013.109 ↗
63. 10.1002/stem.164910.1002/stem.1649 ↗
64. Centeno CJ, Busse D, Kisiday J, et al. Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells. Pain Physician 2008;11:343–353.
65. 10.1016/j.arthro.2013.09.07410.1016/j.arthro.2013.09.074 ↗
66. 10.1016/j.jcyt.2014.01.03510.1016/j.jcyt.2014.01.035 ↗
67. 10.1097/TP.000000000000067810.1097/TP.0000000000000678 ↗
68. 10.1186/s13075-016-1195-710.1186/s13075-016-1195-7 ↗
69. 10.1186/s12967-016-0998-210.1186/s12967-016-0998-2 ↗
70. March L, Hunter D, Ward C, et al. A randomised placebo controlled pilot study of autologous non-expanded adipose-derived mesenchymal stem cells in the treatment of knee osteoarthritis. Intern Med J. 2013;43:4–5.
71. 10.1002/stem.163410.1002/stem.1634 ↗
72. 10.1186/s12967-018-1420-z10.1186/s12967-018-1420-z ↗
73. 10.5999/aps.2012.39.6.58510.5999/aps.2012.39.6.585 ↗
74. 10.1051/sicotj/201700410.1051/sicotj/2017004 ↗
75. 10.1016/j.joca.2015.07.00410.1016/j.joca.2015.07.004 ↗
76. 10.1002/art.3878010.1002/art.38780 ↗
77. 10.1177/036354651455419010.1177/0363546514554190 ↗
78. 10.1097/JSM.0b013e31827c384610.1097/JSM.0b013e31827c3846 ↗
79. 10.2106/JBJS.M.0005810.2106/JBJS.M.00058 ↗
80. 10.5966/sctm.2015-024510.5966/sctm.2015-0245 ↗